Urinary Trivalent Methylated Arsenic Species in a Population Chronically Exposed to Inorganic Arsenic by Valenzuela, Olga L. et al.
250 VOLUME 113 | NUMBER 3 | March 2005 • Environmental Health Perspectives
Arsenic is a ubiquitous element found in
several forms in foods and environmental
media such as soil, air, and water; the pre-
dominant form in drinking water is inorganic
As (iAs), which is both highly toxic and read-
ily bioavailable. iAs is a recognized carcinogen
in humans [National Research Council
(NRC) 2001]. Chronic ingestion of iAs-
contaminated drinking water is therefore con-
sidered the major pathway behind the risk to
human health. It has been estimated that
200 million people worldwide are at risk
from health effects associated with high con-
centrations of As in their drinking water
(NRC 2001). Several other regions in the
world are exposed to levels above the maxi-
mum permissible limit recommended by the
World Health Organization (WHO 1993).
In humans, the chronic ingestion of iAs
(> 500 µg/day As) has been associated with
cardiovascular, nervous, hepatic, and renal
alterations and diabetes mellitus as well as
cancer of the skin, bladder, lung, liver, and
prostate [Agency for Toxic Substances and
Disease Registry (ATSDR) 2000]. Charac-
teristic features of arseniasis include skin
manifestations, such as hyperpigmentation,
hypopigmentation, and hyperkeratosis on the
palms and soles, and skin cancer at later
stages (Cebrian et al. 1983; Schwartz 1997;
Tseng et al. 1968).
In humans, the mechanism by which iAs
exerts its toxic effects is very complex because
its metabolism involves at least five metabo-
lites that can exert toxic effects. The scheme
for the stepwise conversion of arsenite (iAsIII)
into mono-, di-, and trimethylated products
is as follows:
AsIIIO3
3– + CH3
+ → CH3AsVO3
2– +2e–
→ CH3AsIIIO2
2– + CH3
+
→ (CH3)2AsVO2
– + 2e–
→ (CH3)2AsIIIO–+ CH3
+ → (CH3)3AsVO–
Brieﬂy, the metabolic process is carried out in
two processes: a) the reactions of reduction
that convert the pentavalent species to tri-
valency, and b) reactions of oxidative methyla-
tions where iAs is converted to mono-, di-, and
trimethyl arsenic forms (MAs, DMAs, and
TMAsO, respectively). Thus, both pentavalent
methylarsenic (MAsV) and trivalent methy-
larsenic (MAsIII) forms are intermediates or
products of this pathway (Lin et al. 2002;
Thomas et al. 2004).
Using S-adenosylmethionine as a methyl
group donor, As methyltransferase (Cyt19,
EC 2.1.1.138) has been shown to catalyze
reactions, reduction and oxidative methyla-
tion, in rodents and humans (Waters et al.
2004). Other studies have shown the capacity
of two mammalian proteins to reduce iAsV,
glutathione S-transferase omega (GSTΩ,
EC 2.5.1.18) (Zakharyan et al. 2001) and the
purine nucleoside phosphorylase (PNP,
EC 2.4.2.1) (Nemeti et al. 2003; Radabaugh
et al. 2002).
Urinary As is generally regarded as the most
reliable indicator of recent exposure to iAs and
is used as the main biomarker of exposure
(Mushak and Crocetti 1995). In addition, the
urinary profiles of iAs metabolites have fre-
quently been used in epidemiologic studies to
assess the capacity of exposed individuals to
methylate iAs. During almost 20 years, the
methylation of iAs has been generally evaluated
using urinary measurement of iAs (III + V),
MAs (III + V), and DMAs (III + V) in people
exposed to As. Nevertheless, the differentiation
of the trivalent intermediaries of As metabolism
is important because the trivalent methylated
arsenicals, MAsIII and DMAsIII, are more
potent than either iAsIII or iAsV in cytotoxicity
(Styblo et al. 2000), genotoxicity (Mass et al.
2001; Nesnow et al. 2002), and inhibition of
enzymes with antioxidative functions (Lin et al.
2001; Styblo et al. 1997). Therefore, the for-
mation of MAsIII and DMAsIII in the methyla-
tion pathway for iAs may play a signiﬁcant role
in the induction of toxic effects associated with
exposures to iAs.
The goal of this study was to assess the
urinary pattern of As methylation, including
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Chronic exposure to inorganic arsenic (iAs) has been associated with increased risk of various
forms of cancer and of noncancerous diseases. Metabolic conversions of iAs that yield highly toxic
and genotoxic methylarsonite (MAsIII) and dimethylarsinite (DMAsIII) may play a signiﬁcant role
in determining the extent and character of toxic and cancer-promoting effects of iAs exposure. In
this study we examined the relationship between urinary proﬁles of MAsIII and DMAsIII and skin
lesion markers of iAs toxicity in individuals exposed to iAs in drinking water. The study subjects
were recruited among the residents of an endemic region of central Mexico. Drinking-water reser-
voirs in this region are heavily contaminated with iAs. Previous studies carried out in the local
populations have found an increased incidence of pathologies, primarily skin lesions, that are
characteristic of arseniasis. The goal of this study was to investigate the urinary profiles for the
trivalent and pentavalent As metabolites in both high- and low-iAs–exposed subjects. Notably,
methylated trivalent arsenicals were detected in 98% of analyzed urine samples. On average, the
major metabolite, DMAsIII, represented 49% of total urinary As, followed by DMAsV (23.7%),
iAsV (8.6%), iAsIII (8.5%), MAsIII (7.4%), and MAsV (2.8%). More important, the average MAsIII
concentration was signiﬁcantly higher in the urine of exposed individuals with skin lesions com-
pared with those who drank iAs-contaminated water but had no skin lesions. These data suggest
that urinary levels of MAsIII, the most toxic species among identiﬁed metabolites of iAs, may serve
as an indicator to identify individuals with increased susceptibility to toxic and cancer-promoting
effects of arseniasis. Key words: arsenic, arsenic skin lesions, arsenic speciation, hyperkeratosis,
hyperpigmentation, hypopigmentation, metabolism, methylation, trivalent arsenic, trivalent
methylarsenic species, urine metabolites. Environ Health Perspect 113:250–254 (2005).
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Research Articletrivalent methylated metabolites, in an As-
endemic population using freshly collected
samples analyzed as soon as possible to avoid
the oxidation of MAsIII and DMAsIII, even at
temperatures < 0°C (Del Razo et al. 2001;
Gong et al. 2001). Additionally, we compared
the pattern of urinary trivalent methylated
metabolites between persons with and with-
out skin lesions associated with arsenicism in
an endemic Mexican area.
Materials and Methods
Site selection. Study subjects were residents of
Zimapan in the state of Hidalgo, an area
located in the central part of Mexico, approxi-
mately 220 km from Mexico City. It has been
a mining district since the 16th century. By
1810 there were 40 smelters operating in and
around Zimapan (Garcia and Querol 1991).
There have been no active smelters in Zimapan
since the 1940s; however, tailing piles from the
ﬂotation process have accumulated in Zimapan
for > 60 years. Tailings are sediments resulting
from settling of ore’s wastes. Some rocks from
the Zimapan Valley with higher than world
average iAs concentrations for the rock type
(2,550–21,400 mg/kg) were found in all the
tailings (Mendez and Armienta 2003). Most of
the current exposure occurs outside the
Zimapan basin, but old tailings near the edge
of the town are still an iAs pollution source.
Two major pathways contaminate ground-
water with iAs: a) iAs dissolved from ore and
other minerals in the mining district can be
transported through fractures in the limestone
(mainly arsenopyrite) to water sources, and
b) rainwater leaches through surrounding mine
tailing piles (Armienta et al. 1997a). The
National Water Commission of Mexico found
high iAs concentrations in many of the wells in
1992. Water samples collected from springs
and drilled wells (~ 180 m total depth) pre-
sented levels between 21 and 1,100 µg As/L
(Comisión Nacional del Agua 1992).
In 1999, the municipality closed one of
the wells connected to the municipal water
system that contained the highest iAs concen-
tration (1,100 µg/L). This action reduced the
average iAs concentration in the municipal
water from 580 to 350 µg/L. However, > 40%
of the valley residents in this area are not con-
nected to this municipal supply and rely on
local springs and norias (bucket-wheel wells)
for their potable water, and some of these
sources are still heavily polluted with iAs.
Subject selection. We conducted a cross-
sectional study with 104 participants who lived
in areas where their drinking water normally
contained iAs, 76 Zimapan residents exposed
to ≥ 50 µg/L iAs and 28 individuals exposed to
≤ 10 µg/L iAs (controls), in accordance with
the regulations of the Ethical Committee of
the Faculty of Medicine, Juarez University of
Durango. Subjects were recruited through
door-to-door contact. They had to be at least
15 years of age and live in the town for the pre-
vious 2 years. Before enrollment in the study,
each participant read and signed an informed
consent form. Subjects were interviewed by
trained interviewers regarding general charac-
teristics with emphasis in personal habits, his-
tory and habits of water consumption,
smoking habits, and medical, occupational,
and residential histories. They underwent
physical examination looking for typical der-
matologic signs of arseniasis. These signs of
arseniasis were evaluated by medical health care
physicians, who were blind to time and level of
exposure for each subject at the time of physi-
cal examination. The physicians have been
evaluating dermatologic signs of arseniasis in
Mexico for about 10 years. Participants were
asked to exclude seafood from their diets for
the preceding 4 days. Individuals who had
received drugs with well-deﬁned organ toxicity
within the past 4 months or were suffering
chronic alcoholism were excluded. Each fam-
ily’s drinking water was analyzed for total As
(TAs) concentration. The final decision on
study eligibility was based on the measure-
ment of TAs concentration in the household
water source, and approximately 50% of the
iAs-high exposed group presented with at
least one skin sign of arseniasis, such as hypo/
hyperpigmentation, palmoplantar hyper-
keratosis, and ulcerative lesions as described
by Yeh (1973).
Exposure assessment. We estimated the
total liters of drinking water consumed per
day by each subject on the basis of subjects’
statements. Daily estimates of As consumption
were calculated as the product of the number
of liters consumed per day and the As concen-
tration in the subject’s drinking water source.
Cumulative exposure to iAs or time-weighted
iAs exposure (TWE) was calculated using the
duration of exposure, the number of liters
consumed per day, and the historical As con-
centration reported by the Mexican National
Water Commission from 1992 to the present
time (Garcia-Vargas et al. 1994).
Chemicals. Arsenic acid disodium salt
(Na2HAsVO4) and sodium m-arsenite
(NaAsIIIO2), both > 99% pure, were obtained
from Sigma Chemical Co. (St. Louis, MO,
USA). Methylarsonic acid (MAsV) disodium
salt [CH3AsVO(ONa)2; 99% pure] was
obtained from Ventron (Danvers, MA, USA),
and dimethylarsinic acid [DMAsV; as
(CH3)2AsVO(OH); 98% pure] was obtained
from Strem (Newburyport, MA, USA). The
trivalent methylated arsenicals methyloxoarsine
(MAsIIIO; CH3AsIIIO) and iododimethyl-
arsine of DMAsIII [DMAsIIII; (CH3)2AsIIII]
were synthesized by W.R. Cullen (University
of British Columbia, Vancouver, British
Columbia, Canada) using previously described
methods (Cullen et al. 1984; Styblo et al.
1997). Identity and purity of the synthesized
arsenicals were confirmed using 1H nuclear
magnetic resonance, mass spectrometry, and
hydride generation–atomic absorption spectro-
photometry (HG-AAS) as previously described
(Hughes et al. 2000). In aqueous solutions,
MAsIIIO and DMAsIIII are presumed to form
MAsIII and DMAsIII, respectively. Working
standards of these arsenicals that contained
1 µg/mL As were prepared daily from stock
solutions. Sodium borohydride (NaBH4) was
obtained from EM Science (Gibbstown, NJ,
USA). Tris hydrochloride was purchased from
J.T. Baker (Phillipsburg, NJ, USA). Creatinine
kits were purchased from Randox (San Diego
CA, USA). All other chemicals used were at
least analytical grade. Standard reference mate-
rial (SRM) water (SRM 1463c) and urine
[SRM 2670; National Institute of Standards
and Technology (NIST), Gaithersburg, MD,
USA] were used for quality control of TAs in
water and urine analysis, respectively.
Drinking-water collection and processing.
Tap water samples were collected in the
homes of potential subject families using acid-
washed containers transported to the site of
the study by the investigators. We collected a
total of 91 water samples from 80 households
(more than one sample was obtained from
each household if participants used different
sources of water to drink and cook). Water
samples were stored at –20°C until subsequent
assay. Water samples were transported to the
Cinvestav-IPN laboratories in Mexico City
for TAs analysis. TAs was determined by
HG-AAS using a PerkinElmer 3100 spec-
trometer (PerkinElmer, Norwalk, CT, USA),
equipped with a FIAS-200 flow injection
atomic spectroscopy system as reported previ-
ously (Del Razo et al. 1990). All measure-
ments were made using an As electrodeless
discharge lamp. SRM 1463c was used for
quality control of TAs in water analysis. The
certiﬁed TAs concentration in SRM 1463c is
82.1 ± 1.2 µg/L. Replicate analyses of this
SRM using the method described above gave
concentrations of 82.7 ± 1.7 µg/L, which is in
good agreement with the certiﬁed value.
Urine collection and processing. After clini-
cal exploration, all participants were scheduled
for urine sample collection each third day over
3 weeks in groups of 10–12 individuals each
time. Subjects were seen between 0700 and
0800 hr at the local health center, where urine
spot samples were collected with a minimum
of contamination in 250-mL polypropylene
containers that we provided. Urine samples
were immediately frozen in dry ice. To prevent
oxidation of unstable trivalent methylated
arsenicals, frozen urine samples were immedi-
ately transported to Cinvestav-IPN laboratory
and analyzed within 6 hr after collection.
A pH-specific HG-AAS has been opti-
mized to permit simultaneous analysis of all
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iAsV, MAsIII, MAsV, DMAsIII, and DMAsV in
urine (Del Razo et al. 2001). This method is
based on a pH-speciﬁc generation of hydrides
from tri- and pentavalent iAs, MAs, and
DMAs with subsequent chromatography and
determination of As contents in HG-AAS.
The HG-AAS apparatus was based on the
design of Crecelius et al. (1986). For hydride
generation at ≤ pH 2, 1 mL sample urine,
5 mL deionized water, and 1 mL 6 M
hydrochloric acid (HCl) were placed into the
reaction vessel. This mixture had a ﬁnal pH of
1–2. For hydride generation at pH 6, 1 mL
sample urine, 5 mL deionized water, 1 mL
2.5 M Tris-HCl, and 0.06 M NaOH buffer,
pH 6, were placed into the reaction vessel.
This mixture had a ﬁnal pH of approximately
6. At either pH, thorough mixing of the con-
tents of the reaction vessel was followed by
injection into the reaction vessel of 1 mL of a
4% solution of NaBH4 in 0.02 M NaOH.
Cold-trapped arsines were released from the
U-tube by its removal from the liquid nitro-
gen and application of heat, for separation of
the later arsines for a gradient of temperature.
We used SRM 2670 to validate analysis of
TAs; SRM 2670 consists of two bottles of
urine—one containing an elevated concentra-
tion of As and one containing a normal con-
centration. The certiﬁed TAs concentration in
the elevated urine is 480 ± 100 µg/L. As in
normal urine is not certified; however, the
NIST provides a reference value of 60 µg/L.
Replicate analyses of these SRMs using the
method described above give concentrations of
507 ± 17 µg/L and 64 ± 5 µg/L, respectively,
which are in good agreement with the certiﬁed
and reference values. The TAs concentration in
urine samples reported in this article is the sum
of the concentrations of iAsIII, iAsV, MAsIII,
MAsV, DMAsIII, and DMAsV.
Creatinine in urine. Urinary creatinine
was measured by the Jaffe reaction using a
Randox commercial kit. Arsenical species
concentrations in urine were corrected for
creatinine concentration as an indication of
urine dilution.
Statistical methods. Data analysis was car-
ried out using Stata 8.0 statistical software
(Stata Corp., College Station, TX, USA).
Arsenical values were transformed to a log scale
in order to calculate means and range, to per-
form statistical comparisons between groups,
and to evaluate potential confounding factors.
We used Mann-Whitney tests to compare uri-
nary As metabolites among exposed groups
with and without lesions. Potential confound-
ing risk factors evaluated included age, sex,
sunlight exposure, and TWE.
Results
Eighty families with a total of 104 participants
completed the sampling protocol (Table 1).
Because of the lack of good job opportunities
in this area, most of the young men emigrate
out of the country; in consequence, most of
the subjects (90%) were female. The concen-
tration of TAs in home drinking water of study
participants ranged from 1 to 1,054 µg/L. In
24 homes (30%), the subjects drank bottled
water in addition to municipal water.
Urine samples from both controls and
individuals chronically exposed to high iAs by
consumption of drinking water containing
this metalloid were analyzed to determine the
concentrations of iAsIII, MAsIII, and DMAsIII.
Arsenical values were adjusted by creatinine
concentration. Urinary creatinine measure-
ments ranged from 105 to 3,230 mg/L, with
an average of 595 mg/L. Average urinary con-
centrations of trivalent and pentavalent As
species in the total study group are shown in
Table 2. Methylated trivalent arsenicals were
detected in 98% of analyzed urine samples. In
addition, trivalent arsenicals (iAsIII + MAsIII +
DMAsIII) were the predominant species in
urine samples (65%). On average, the major
metabolite, DMAsIII, represented 49% of total
urinary As, followed by DMAsV (23.7%),
iAsV (8.6%), iAsIII (8.5%), MAsIII (7.4%),
and MAsV (2.8%).
Cutaneous signs of arsenicism were
observed in 55 individuals from the group
exposed to ≥ 50 µg/L As in drinking water.
The type and proportion of cutaneous signs
observed in participants of this study are
shown in Table 3. Hyperkeratosis in the palm
or sole was the most frequent skin sign of
arsenicism (56.6%).
Table 4 summarizes the average arsenical
concentrations according to the level of As
exposure and the presence of skin lesions.
Interestingly, in the high-As-exposure group,
subjects presenting cutaneous signs had signif-
icant increases in the concentration of MAsIII.
In addition, the average of relative proportion
of urinary MAsIII was marginally higher in
exposed individuals with skin lesions com-
pared with those who drank iAs-contaminated
water but had no skin lesions (Table 5).
The conditional logistic regression model
was based on 76 subjects exposed to ≥ 50 µg/L
As in drinking water; this model was adjusted
by age, sex, and TWE. The risk of occurrence
of arseniasis related to both absolute and rela-
tive quantity of MAsIII was significant
(p < 0.008 and < 0.004, respectively). The
odds ratios (OR) for the subjects having hyper-
keratosis plantar was estimated to be 1.06
[95% conﬁdence interval (CI), 1.03–1.19] for
concentration of MAsIII and 1.22 (95% CI,
1.07–1.44) for relative proportion of MAsIII.
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Table 2. Concentration and relative proportion of As species in residents of the Zimapan area (n = 104).
iAs metabolite in urine Concentration (µg/g creatinine) Relative proportion (%)
iAsV 5.84 (1–65.5) 8.6
iAsIII 4.46 (0.1–172.3) 8.5
MAsV 1.45 (0.1–28.3) 2.8
MAsIII 4.93 (0.1–101.9) 7.4
DMAsV 14.56 (1–710) 23.7
DMAsIII 30.75 (0.1–506.3) 49
TAs 84.85 (9.1–1398.1) 100
Concentration of metabolites of As in urine are reported as geometric mean (range).
Table 1. Demographics of the study population.
Low iAs exposure High iAs exposure
Characteristics Control Without skin lesions With skin lesions
No. of subjects 28 21 55
Sexa
Male 2 (7.1) 1 (4.8) 7 (14.6)
Female 26 (92.9) 20 (95.2) 48 (85.4)
Age (years)  35 (18–50) 35 (21–49) 35 (15–51)
Sunlight exposure (hours) 2.3 (0–8) 2.2 (0–8) 2.8 (0–9)
TAs concentration in drinking water (µg/L) 1.6 (1–6) 117 (50–1,504) 115 (50–658)
Duration of iAs exposure (years)b 26 (4–50) 21 (4–49) 26 (4–51)
TWE (mg) 0.01 (0.01–0.06) 5.8 (0.02–16.3) 9.3 (0.23–26.9)*
Values are mean (range) except where noted. 
aValues are mean (%). bDuration of well water consumption. *Statistically significant difference (p < 0.05) between the
exposed individuals with and without skin lesions.
Table 3. Distribution of skin lesion in iAs-exposed
subjects (n = 76).
Frequency [no. (%)]
Skin lesion With lesion w/o lesion
Hypopigmentation 36 (47.4) 40 (52.6)
Hyperpigmentation 29 (38.2) 47 (61.8)
Hypo-/hyperpigmentation 9 (11.8) 67 (88.2)
Hyperkeratosis on the palms 33 (43.4) 43 (56.6)
Hyperkeratosis on the soles 30 (39.5) 46 (60.5)
Hyperkeratosis on the palms  43 (56.6) 33 (43.4)
or soles
Keratosis on the trunk 17 (22.4) 59 (77.6)
Cutaneous horns 4 (5.3) 72 (94.7)
Bowen’s disease 1 (1.3) 75 (98.7)
Squamous cell carcinoma 1 (1.3) 75 (98.7)
w/o, without. Frequency was calculated for 76 subjects
exposed to ≥ 50 µg/L As in drinking water.Even though DMAsIII was the main species
found in urine, neither its concentration nor its
relative proportion was associated with the risk
of As skin lesions (data not shown).
Another variable, independent of iAs
metabolites, that was significantly associated
with the presence of hyperkeratosis plantar
(p = 0.003) in the group who drank water
containing As > 50 µg/L was the lifetime iAs
exposure, estimated as TWE (OR = 1.20;
95% CI, 1.06–1.35).
Discussion
MAsIII and DMAsIII in urine. The analysis of
urinary trivalent methylated metabolites of
iAs using freshly collected urine samples,
within 6 hr of collection to reduce differences
in handling among samples and to minimize
the extent of oxidation of trivalent arsenicals
before analysis, allowed detection of the pres-
ence of MAsIII and DMAsIII in 98% of the
urine collected, even in urine samples from
subjects with low As exposure (≤ 10 µg/L in
drinking water; Table 4). The optimization of
As speciation techniques has only recently per-
mitted analysis of oxidation states of As in
methylated metabolites. Initial studies using
the optimized techniques detected small
amounts of MAsIII and/or DMAsIII in urine
from residents exposed to iAs in drinking
water in several geographical regions, includ-
ing Romania (Aposhian et al. 2000), Inner
Mongolia (Le et al. 2000), Mexico (Del Razo
et al. 2001), and West Bengal (Mandal et al.
2001). However, most of these studies ana-
lyzed urine samples that were stored for an
extended time after collection. Because MAsIII
and DMAsIII are rapidly oxidized even at tem-
peratures < 0°C (Del Razo et al. 2001; Gong
et al. 2001), these studies probably under-
estimated the concentrations of these metabo-
lites. In contrast, analyses of freshly collected
urine samples in this study showed that
methylated trivalent arsenicals (MAsIII and
DMAsIII) are in fact prevalent urinary metabo-
lites of iAs (Table 2). DMAsIII also was
detected only when fresh void urine was col-
lected from DMAsV-fed rats (Cohen et al.
2002). Csanaky and Gregus (2002) reported
that intravenously injected iAs was excreted
mainly as MAsIII, and Suzuki et al. (2001)
reported that this excreted MAsIII was conju-
gated by glutathione [MAsIII(GS)2] in rat bile.
Urinary detection of methylated and
dimethylated arsenicals containing As in both
oxidation states indicates that metabolism of
As involves changes in the oxidation state of As
during methylation. It is likely that interactions
of trivalent iAs metabolites with proteins and
other cellular constituents are responsible for
retention and toxic effects of As in tissues of
animals and humans exposed to iAs. A study
with a population chronically exposed to iAs
from drinking water indicated that methylated
arsenicals are also retained in tissues (Aposhian
et al 1997, 2000). These As-exposed indi-
viduals were treated with an As chelator,
2,3-dimercaptopropane-1-sulfonic acid
(DMPS), which resulted in a massive release
of MAs, including MAsIII, in urine, suggesting
that DMPS mobilized tissue depots of iAs.
Skin lesions and trivalent methylated
metabolites of iAs. Skin keratosis and changes
in skin pigmentation are two hallmark signs
of arseniasis. Many residents of the Zimapan
area had skin lesions related to iAs exposure
(Armienta et al. 1997b) (Table 3). According
to the historical values of As in drinking
water, most of the families who participated
in this study were exposed to extremely high
As concentrations at least from 1992 to 1999.
After this time, the level of concentration of
As in water has been decreased because the
municipality closed one of the wells con-
nected to the municipal water system that
contained the highest iAs concentration
(1,100 µg/L). In addition, several residents
previously drank bottled water with normal
values of As instead of drinking water from
the municipal system. This fact can explain
the great prevalence of dermatoxicity, despite
the moderate concentration of arsenicals in
urine observed in the present study (Table 4).
We also assessed the proﬁle of iAs metabo-
lites on dermatoxicity (Table 3). Previous
studies in other regions, such as the Lagunera
Region in Mexico (Del Razo et al. 1997) and
Taiwan (Yu et al. 2000), showed that subjects
with arseniasis were more likely to have a
higher concentration of MAs in urine than
were exposed individuals who had did not
have arseniasis; at that time, the speciated
arsenical concentrations in urine were made
without mentioning their oxidation state.
Recent advent of techniques for speciation of
As has helped establish the speciation of As
according to oxidation states.
Importantly, trivalent methylated metabo-
lites, especially DMAsIII, were not stable in
human urine and oxidized quickly to yield
pentavalent MAsV and DMAsV (Del Razo
et al. 2001). As noted above, these samples
were analyzed within 6 hr of collection to
reduce differences among samples in handling
and to minimize the extent of oxidation of
AsIII before analysis.
Interestingly, in our study the iAs-exposed
individuals bearing skin signs of arsenicism had
signiﬁcantly higher urinary relative proportions
and concentrations of MAsIII. These data sug-
gest that a high output of MAsIII in urine may
predict increased susceptibility to arseniasis.
MAsIII and DMAsIII have been reported
to be highly toxic in mammalian cells (Styblo
et al. 2000, 2002) and genotoxic (Mass et al.
2001; Nesnow et al. 2002). The reason for
the high toxicity of methylated trivalent
arsenicals has not been adequately explained,
except that methylated trivalent arsenicals
exert genotoxicity via reactive oxygen species
(Nesnow et al. 2002). Although the compara-
tive toxicity of MAsIII(GS)2 was about nine
times higher than that of iAsIII, the accumula-
tion rate of MAsIII(GS)2 was 40 times higher
than that of iAsIII. These results suggest that
MAsIII(GS)2 was more toxic than iAsIII, at
least in part due to the more efficient accu-
mulation of As in cells (Hirano et al. 2004).
Moreover, Vega et al. (2001) showed that
normal human epidermal keratinocytes
exposed to low doses (0.001–0.01 µM) of
MAsIII stimulated expression of certain pro-
inflammatory cytokines and growth factors
that are critical to maintaining homeostasis
and barrier integrity in the skin, suggesting
that the overexpression of these products can
lead the skin pathologic processes.
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Table 4. Urinary pattern of iAs species in humans exposed to As through drinking water in the Zimapan
area, according to level exposition and the presence of As skin lesions (n = 104).
Metabolite concentration of iAs in urine (µg/g creatinine)
Control Exposed, without lesions Exposed, with lesions
As species (n = 28) (n = 21) (n = 55)
IAsV 3.6 (1.0–10.5) 6.1 (2.0–37.2) 8.2 (2.4–65.5)
IAsIII 1.6 (0.1–9.7) 6.9 (1.5–101.6) 6.3 (0.3–172.3)
MAsV 0.6 (0.1–5.5) 1.8 (0.3–16.6) 2.0 (0.1–28.3)
MAsIII 2.2 (0.4–9.6) 4.8 (0.1–24.9) 7.5 (0.2–101.9)*
DMAsV 7.4 (1.8–38.5) 15.9 (1.0–226.5) 19.8 (1.0–710.1)
DMAsIII 7.9 (0.1–65.4) 48.1 (2.2–206) 51.9 (1.4–506.3)
TAs 33.3 (9.1–106) 116 (61.2–371.7) 121.2 (51.9–1,398)
Values shown are geometric mean (range).
*Statistically signiﬁcant difference (p < 0.05) between the exposed individuals with and without skin lesions (by Mann-
Whitney test).
Table 5. Comparison of mean percentage of As
species in urine among As-exposed subjects with
and without skin lesions.
Percent As-exposed subjects
Without lesions With lesions
As species (n = 21) (n = 55)
iAsV 6.5 7.9
iAsIII 10.9 8.0
MAsV 3.5 2.3
MAsIII 5.9 7.7*
DMAsV 21.5 23.1
DMAsIII 51.7 51.0
*Statistically marginal difference (p = 0.072) between the
exposed individuals with and without skin lesions (by
Mann-Whitney test).Article | Valenzuela et al.
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Another possible mechanism for higher
toxicity of trivalent arsenicals compared with
the corresponding pentavalent forms is that
trivalent species have a higher afﬁnity for thiol
compounds (Shiobara et al. 2001).
In light of these observations, biomethyla-
tion of iAs, a process yielding toxic trivalent
methylated metabolites, appears to be a mecha-
nism of activation of As as a toxin and possibly
as a carcinogen. Because of the adverse biologic
effects of these metabolites, the analysis of uri-
nary MAsIII may serve as an effective tool for
the evaluation of health risks associated with
exposure to iAs.
There were no significant associations
between other confounding risk factors, such
as duration of sunlight, and skin lesions (data
not shown). 
Another important factor associated with
the presence of As skin lesions was the lifetime
exposure of As evaluated as TWE. Table 1
shows the signiﬁcant difference between this
variable between exposed As subjects, demon-
strating that the magnitude of exposure is
directly related to the presence of skin lesions.
In other words, the basic principle of dose–
response relationship was fulfilled for the
presence of As skin lesions.
The major limitations of this study are the
small sample population and the fact that most
of the participants were female. Previous
reports have indicated that age, dose, preg-
nancy, and sex are among factors that affect the
urinary proﬁles of iAs metabolites (Del Razo
et al. 1997; Hughes et al. 2000; Yu et al.
2000). Results obtained in this study may not
generalize to males or to the entire population.
This study provides novel data on the pat-
tern of trivalent and pentavalent metabolites
of iAs clearance in fresh urine from a popula-
tion exposed to iAs in drinking water. Unlike
other studies, in which urine samples were
stored for several weeks before analysis, this
study shows that MAsIII and DMAsIII in urine
are predominant As species compared with
their corresponding pentavalent arsenicals.
MAsIII, the most potent toxicant in the
entire metabolic pathway of iAs, could be
mainly responsible for the toxic and carcino-
genic effects of iAs exposure, and its detection
and quantiﬁcation in human populations can
assist in risk assessment and could be the cause
of As carcinogenesis. Our ﬁndings support the
view that the extent and character of adverse
effects associated with iAs exposures are at least
in part determined by the rate of the formation
and by the composition of iAs metabolites.
Further research in other populations
with arseniasis is needed to confirm the
potential relationship between the concentra-
tions of MAsIII in biologic samples from
human populations and the little-understood
etiology of hyperkeratosis, skin hypo- or
hyperpigmentation, and cancer that can result
from chronic iAs exposure.
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